July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis
Author Affiliations & Notes
  • Armin R Afshar
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States
  • Bertil E Damato
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
    Oxford Eye Hospital and the Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom
  • Jay M Stewart
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Ritu Roy
    Epidemiology & Biostastics, University of California, San Francisco, San Francisco, California, United States
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States
  • Adam Olshen
    Epidemiology & Biostastics, University of California, San Francisco, San Francisco, California, United States
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States
  • Boris Bastian
    Dermatopathology, University of California, San Francisco, San Francisco, California, United States
    Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Armin Afshar, None; Bertil Damato, None; Jay Stewart, Achaogen (C), Genentech (C), Merck (C); Ritu Roy, None; Adam Olshen, None; Boris Bastian, None
  • Footnotes
    Support  National Eye Institute, 1K23EY027466 (K23 Mentored Patient-Oriented Research Career Development Award to A.R.A.), EY002162 (Core Grant for Vision Research); Research to Prevent Blindness, Inc., New York, NY (an unrestricted grant and a Career Development Award A.R.A.); National Cancer Institute, 1R35CA220481 (an Outstanding Investigatory Award to B.C.B.), and 5P30CA082103 (Cancer Center Support Grant to R.R. and A.B.O.), and That Man May See, Inc., San Francisco, CA (seed grants to A.R.A).
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 752. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Armin R Afshar, Bertil E Damato, Jay M Stewart, Ritu Roy, Adam Olshen, Boris Bastian; Next-generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis. Invest. Ophthalmol. Vis. Sci. 2019;60(9):752.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To clinically utilize a pan-cancer, targeted next-generation sequencing assay in uveal melanoma, and to correlate results with gene expression profiling and predictive factors for metastasis.

Methods : Cohort study. Tumor samples of adult UM patients were analyzed with the UCSF500 60 and GEP. Main outcomes were copy number changes in chromosomes 1, 3, 6 and 8 and mutations in GNAQ, GNA11, SF3B1, EIF1AX, BAP1, SRSF2, U2AF1 and PLCB4. Chromosome 3 loss (a metastasis predictor) was tested for correlation with GEP class, tumor characteristics (largest basal diameter, thickness, ciliary body involvement, extraocular extension) and histology (presence of epithelioid cells, closed loops, mitotic count).

Results : The 62 patients had a mean age of 58.6 years (range, 24 – 88). Chromosome 3 loss was detected in 30 and was associated with larger basal tumor diameter (Wilcoxon test, p=0.015), higher thickness (Wilcoxon test, p=0.016) and TNM stage (Fisher test, p=0.006), epithelioid cytology (Fisher test, p=4*10-6), BAP1 mutation (Fisher test, p=8*10-12) and chromosome 8q gain (Fisher test, p=10*10-9). Class 2 tumors were much more likely to have chromosome 3 loss compared to Class 1 (odds ratio, 121; p=6*10-10). Eleven patients developed metastatic UM, of which five died during the study. All metastatic cases had chromosome 3 loss, 8 gain, BAP1 mutation and Class 2 GEP. Five Class 1 tumors had chromosome 3 loss.

Conclusions : A targeted, next-generation sequencing assay detected chromosomal copy number changes and missense mutations that correlate strongly with metastasis predictors in uveal melanoma, including gene expression profiling results.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×